Everything below concerns thymosin beta-4 fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
American Samoa - Scouting in American Samoa - Aloha Council of the Boy Scouts of America Guam - Scouting in Guam - Aloha Council of the Boy Scouts of America Northern Marianas Islands - Scouting in the Northern Mariana Islands - Aloha Council of the Boy Scouts of America Puerto Rico - Puerto Rico Council of the Boy Scouts of America United States Virgin Islands - Scouting in the United States Virgin Islands is the responsibility of National Capital Area Council of the Boy Scouts of America Antarctica
=== Benefits of GSK-3β inhibitors === In diabetes, GSK-3β inhibitors increase insulin sensitivity, glycogen synthesis, and glucose metabolism in skeletal muscles, and reduce obesity by affecting the adipogenesis process. GSK-3β is also over expressed in several types of cancers, like colorectal, ovarian, and prostate cancer. GSK-3β inhibitors also aid in the treatment of Alzheimer's disease, stroke, and mood disorders, including bipolar disorder. In vitro studies have shown the beneficial effects of GSK-3 inhibitors in lung cancer, ovarian cancer and neuroblastoma.
Human MHC class I and II are also called human leukocyte antigen (HLA). To clarify the usage, some of the biomedical literature uses HLA to refer specifically to the HLA protein molecules and reserves MHC for the region of the genome that encodes for this molecule, but this is not a consistent convention. The most studied HLA genes are the nine classical MHC genes: HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. In humans, the MHC gene cluster is divided into three regions: classes I, II, and III. The A, B and C genes belong to MHC class I, whereas the six D genes belong to class II. MHC alleles are expressed in codominant fashion. This means the alleles (variants) inherited from both parents are expressed equally:
Mahathir also strengthened political and economic cooperation with China, whilst maintaining diplomatic ambivalence on security issues to avoid escalating territorial disputes in the South China Sea. He openly criticised China's involvement in Malaysia's communist insurgency, but downplayed any military threat from China after the Cold War ended. In 1985, Mahathir visited China for the first time as prime minister, where he met Chinese leader Deng Xiaoping, establishing a new level of trust that laid the foundation for Malaysia-China relations and set the stage for decades of economic and diplomatic growth. Later, he visited China again in 1993, 1994, 1996, 1999, and twice in 2001. In the early 1990s, Mahathir played a key role in engaging China with ASEAN despite South China Sea disputes, particularly in the post-Tiananmen and post-Cold War contexts, paving the way for then Chinese Foreign Minister Qian Qichen to attend the ASEAN meeting's opening ceremony in July 1991 as a guest of the Malaysian government, and eventually leading to China's upgrade to ASEAN's dialogue partner in 1996. Amidst the Asian financial crisis, Mahathir also led several large delegations to China and Russia to seek regional economic cooperation. Besides that, Mahathir also had significant interactions with Taiwan, especially during the 1980s and 1990s, when economic ties between the two sides were at their strongest despite the lack of formal diplomatic relations.
When cannabis is cultivated for its psychoactive or medicinal properties, male plants will often be separated from females. This prevents fertilization of the female plants, either to facilitate sin semilla flowering or to provide more control over which male is chosen. Pollen produced by the male is caught and stored until it is needed. When a male plant of one strain pollinates a female of another strain, the seeds will be F1 hybrids of the male and female. These offspring will not be identical to their parents. Instead, they will have characteristics of both parents. Repeated breeding results in certain characteristics appearing with greater regularity. It is impossible for a hermaphrodite to create any male-only seeds. A hermaphrodite may create female only seeds and hermaphrodite seeds. Also the female-only seeds may carry the hermaphrodite trait. Hybridization is the process of plants and animals breeding. Natural wind currents help speed up this hybridization process and promotes a positive growth. Some plants produce many seeds while some produce little to none depending on how it is bred. If seeds are produced traits from both the original parents will be expressed. Techniques such as mutation breeding are used to develop new strains using irradiation or chemical mutagens such as colchicine. Various companies have been experimenting with creating new strains using genetic engineering techniques.
Sources: en.wikipedia.org
enzyme A protein which acts as a catalyst for a biological process by accelerating a specific chemical reaction, typically by binding one or more substrate molecules and decreasing the activation energy necessary for the initiation of a particular reaction involving the substrate(s). Enzymatic catalysis often results in the chemical conversion of the substrate(s) into one or more products, which then inhibit or permit subsequent reactions. All metabolic pathways consist of a series of individual reactions which each depend upon one or more specific enzymes to drive them forward at rates fast enough to sustain life.
==== Reaction with lipids ==== Hypochlorous acid reacts with unsaturated bonds in lipids, but not saturated bonds, and the ClO− ion does not participate in this reaction. This reaction occurs by hydrolysis with addition of chlorine to one of the carbons and a hydroxyl to the other. The resulting compound is a chlorohydrin. The polar chlorine disrupts lipid bilayers and could increase permeability. When chlorohydrin formation occurs in lipid bilayers of red blood cells, increased permeability occurs. Disruption could occur if enough chlorohydrin is formed. The addition of preformed chlorohydrin to red blood cells can affect permeability as well. Cholesterol chlorohydrin have also been observed, but do not greatly affect permeability, and it is believed that Cl2 is responsible for this reaction. Hypochlorous acid also reacts with a subclass of glycerophospholipids called plasmalogens, yielding chlorinated fatty aldehydes which are capable of protein modification and may play a role in inflammatory processes such as platelet aggregation and the formation of neutrophil extracellular traps.
=== Startup of Poiseuille flow in a pipe === When a constant pressure gradient G = −dp/dx is applied between two ends of a long pipe, the flow will not immediately obtain Poiseuille profile, rather it develops through time and reaches the Poiseuille profile at steady state. The Navier–Stokes equations reduce to
== See also == Le Grand Saut Lockheed U-2 Overshooting top Ozone depletion Batterie Pommern (the first projectile to reach the lower stratosphere) Paris Gun (projectile was the first artificial object to reach the upper stratosphere) Perlan Project Project Excelsior, world record for highest recorded jump 1961–2012 Red Bull Stratos, world record for highest recorded jump 2012–2014 RQ-4 Global Hawk Service ceiling Upper-atmospheric lightning Sudden stratospheric warming
== How to determine GR == The index is derived from a mathematical model of insulin-glucose homeostasis that incorporates fundamental physiological motifs. For diagnostic purposes, it is calculated from fasting insulin and glucose concentrations with:
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.